Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study.

Alejandro VallejoMdC MolanoM Monsalvo-HernandoF Hernández-WaliasM Fontecha-OrtegaJ L Casado

Published in: HIV medicine (2019)

HIV-1-infected patients receiving dual regimens showed similar or even lower levels of inflammatory and activation markers compared with those found in patients who received ongoing triple therapy. Of note, similar data were obtained in patients with low nadir CD4 count.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
human immunodeficiency virus
hiv positive
hiv aids
oxidative stress
electronic health record
stem cells
machine learning
peripheral blood
mesenchymal stem cells
data analysis